Panitumumab
Approved medicineAlso known as ABX-EGF, Vectibix.
Recent clinical, regulatory, research and industry developments relating to this drug.
Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer.
Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer.
Profile
Canonical identifiers, marketed brand names and mechanism, resolved across RxNorm, ChEMBL and ATC.
Research activity
Key research shaping understanding of this drug, combining the latest publications with the most influential evidence.
Major research themes7
Journals, researchers & institutions
- Journal of clinical oncology : official journal of the American Society of Clinical Oncology4
- BMC gastroenterology1
- Clinical cancer research : an official journal of the American Association for Cancer Research1
- JAMA network open1
- Nature medicine1
- Siena S4
- Bardelli A2
- Quirke P2
- Sartore-Bianchi A2
- Wolf M2
- Aghaei F1
- Akagi K1
- Akazawa N1
- School of Medicine3
- Aarhus University1
- Affiliated Anqing First People's Hospital of Anhui Medical University1
- Anqing Municipal Hospital1
- Azienda Ospedaliero-Universitaria Pisana1
- Calderdale and Huddersfield NHS Foundation Trust1
Related diseases
Regulator-approved indications and conditions co-mentioned with this drug across the research literature. Number shows shared papers.
Related drugs
Drugs sharing diseases, protein targets and literature with this one. Ranked by graph evidence (shared targets + diseases weighted above co-mentions).
Studied across 5 of the same disease areas as Panitumumab in the shared literature.
Studied across 5 of the same disease areas as Panitumumab in the shared literature.
Studied across 5 of the same disease areas as Panitumumab in the shared literature.
Studied across 5 of the same disease areas as Panitumumab in the shared literature.
Studied across 5 of the same disease areas as Panitumumab in the shared literature.
Studied across 4 of the same disease areas as Panitumumab in the shared literature.
Studied across 4 of the same disease areas as Panitumumab in the shared literature.
Studied across 3 of the same disease areas as Panitumumab in the shared literature.
- RxNorm (U.S. National Library of Medicine) — drug identity
- Europe PMC — research literature